Mahlangu J, Levy H, Kosinova MV, Khachatryan H, Korczowski B, Makhaldiani L, et al. Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety. Res Pract Thromb Haemost. 2021;5(6):e12576.